NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT04716010 2023-08-18Developing and Evaluating Product MessagingUniversity of North Carolina, Chapel HillPhase NA Completed4,160 enrolled 26 charts